Hepatocellular carcinoma (HCC) is clearly age-related and represents one of the deadliest cancer types worldwide. Due to globally increasing risk factors including metabolic disorders, the incidence rates of HCC are still rising. However, the molecular hallmarks of HCC remain poorly understood. Neuropeptide Y (NPY) and NPYreceptors represent a highly conserved, stress-activated system which is involved in diverse cancer-related hallmarks including aging and metabolic alterations, but its impact on liver cancer had been unclear. Here, we observed increased NPY5-receptor (Y5R) expression in HCC which correlated with tumor growth and survival.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer related mortality worldwide and one of the cancers with still increasing incidence rates (1) .
Major risk factors are chronic infection with hepatitis B and C viruses and alcohol abuse (1) . However, also non-alcoholic fatty liver disease (NAFLD) which is associated with obesity, insulin resistance, and type 2 diabetes, represents an increasingly recognized trigger for HCC development, especially in developed countries (1, 2) . In this context, advanced age has been reported to predispose to HCC and indeed, HCC is mainly affecting those in the age of 65 years and older (3) . Likewise, aging is recognized as significant and independent risk factor for cancer (4, 5) . Hallmarks of cancer development and progression resemble hallmarks of aging, including cellular stress, autophagy, and deregulated nutrient sensing which is correlated with metabolic disorders such as obesity, insulin resistance and NAFLD (6, 7) .
Human aging is tightly linked to activation of the stress-induced sympathoadrenergic system (8, 9) . Moreover, sympathoadrenergic signaling has emerged as a strong promoter of several cancer types (10) (11) (12) (13) . Sympathoadrenergic effects are mediated by catecholamines and the highly conserved neuropeptide Y (NPY). NPY is one of the most widely expressed neurotransmitters in the central and peripheral nervous systems (14) . NPY signals via binding and activation of the G-protein coupled receptors Y1R, Y2R, and Y5R (15) . Herewith, NPY plays a crucial role in various biological processes including cortical excitability, stress response, food intake, circadian rhythms and cardiovascular function (16) . Several milestone studies also suggested key roles of the NPY-system in the regulation of diverse common hallmarks of aging, metabolic disorders and cancer (17) , including autophagy (18) , nutrient sensing, caloric restriction, appetite regulation (19) (20) (21) , mitochondrial dysfunction (22) , cell proliferation (23) and hematopoietic stem-and progenitor-cell properties like migration and intra-/extravasation (24) .
With regards to the liver, systemic NPY levels have been described as potent modulators of chronic liver disease (25) (26) (27) (28) . NPY affects hepatic lipid and glucose metabolism in a way favoring the development of hepatic steatosis, and knockdown of NPY in the hypothalamus promotes hepatic insulin sensitivity in rats (29) . Accordingly, transgenic overexpression of NPY in noradrenergic neurons increased hepatic levels of triglycerides and cholesterol in mice (30) . Furthermore, NPY controls hepatic very low-density lipoprotein (VLDL)-triglyceride secretion via the sympathetic nervous system (31) . Moreover, an in vitro study revealed that NPY promoted the proliferation of activated hepatic stellate cells which could impact hepatic fibrosis (28) . Further studies demonstrated pronounced vasoactive effects of NPY in portal hypertension, which represents a life-threatening complication of advanced liver cirrhosis (25) (26) (27) .
However, the role of the NPY-system in liver cancer remained elusive and has now been addressed in this study.
RESULTS

Enhanced Y5-receptor expression in a spontaneous mouse model of liver cancer and in patients with hepatocellular carcinoma
Although spontaneous hepatocarcinogenesis in aged C3H/HeN mice was first described in the year 1960, the underlying mechanisms are still unknown (32) (33) (34) (35) (36) (37) (38) .
Since the NPY-system was linked to hallmarks of aging, C3H/HeN mice were chosen as a model system to explore age-related gene expression patterns of the NPY-system in hepatocarcinogenesis. Eighty percent of aged (>18 months) male C3H/HeN mice exhibited macroscopic liver tumors (Figure 1A) . Histological analysis revealed diverse HCC-related growth patterns representing inter-and intra-tumorous heterogeneity as frequently observed in murine and human HCC (39) (40) (41) (Figure 1B) . Analysis of surrounding non-tumorous liver tissue revealed that as compared with young mice, significantly higher Y5R mRNA expression was detected in aged mice, while Y1R, Y2R and NPY expression levels showed no age-dependent differences (Figure 1C) . Agedependent upregulation of hepatic Y5R (but not Y1R and Y2R) mRNA levels was also found in Gene Expression Omnibus (GEO) datasets derived from mouse and rat models (Figure S1A,B) . On the protein level, immunohistochemical analysis confirmed higher Y5R expression in livers of aged as compared with young C3H/HeN mice ( Figure 1D; Figure S1C ).
Strikingly, in HCC tissues of aged C3H/HeN mice, Y5R mRNA and protein levels were even further upregulated as compared to corresponding non-tumorous liver tissues (Figure 1E,F; Figure S1D ), while no cancer-related upregulation was found for NPY, Y1R and Y2R (Figure 1E) .
Applying patient-derived samples, Y5R mRNA and protein expression levels were confirmed to be low in non-tumorous liver tissues but also increased with age ( Figure  1G ; Figure S1E-G; Table S3 ). Moreover, Y5R mRNA levels were further upregulated in human HCC tissues ( Figure 1H) . Immunohistological analysis of a tissue microarray (TMA) comprising paired samples of human HCC tissues and corresponding nontumorous liver samples of the same patient (42) (43) (44) confirmed strong expression and marked upregulation of Y5R protein expression in HCC (Figure 1I; Figure S1H ,I; Table S1 ).
Overexpression of both mRNA and protein levels of Y5R pointed to transcriptional upregulation in HCC. Screening of the "Catalogue of Somatic Mutations in Cancer" (COSMIC) database revealed age-associated hypomethylation of a CpG-island within the Y5R gene applying human "The Cancer Genome Atlas" (TCGA)-derived HCC samples ( Figure S1J ). Further analysis (applying the "MethHC" database (45) and the same TCGA cohort) revealed age-related hypomethylation of four additional CpG-sites within the Y5R promotor region, which was inversely correlated with Y5R expression ( Figure 1SK,L) . These findings link age-dependent differential methylation of Y5R with enhanced gene expression in HCC. Alterations in DNA-methylation have been described as a molecular link between aging and caner (46) , were shown to occur in most cancer types and can induce genomic instability and liver cancer formation (47) (48) (49) .
Together, the upregulation of Y5R expression in liver cancer prompted us to ask whether this NPY-receptor might have functional impact in HCC.
Y5R enhances tumorigenicity of HCC and correlates with tumor progression and poor survival
Y5R was also strongly overexpressed in human HCC cell lines as compared with primary human hepatocytes (Figure 2A,B) . Its ligand NPY was abundantly detected in the serum which had been added to the cell culture medium for functional in vitro analysis ( Figure S2A) . Si-RNA-Pool-mediated knockdown of Y5R ( Figure S2B) induced strong reduction of Ki-67 expression and proliferation in HCC cells (Figure 2C,D; Figure S2C ). Fitting to these in vitro findings, Y5R expression levels correlated with CyclinD1 and Ki67 expression in HCC tissues (Figure 2E; Figure S2D ).
Furthermore, Y5R-knockdown markedly reduced both number and size of colonies formed by HCC cells applying clonogenicity assays (Figure 2F; Figure S2E ). Stem cell properties including enhanced clonogenicity are well-known to contribute to HCC development and progression (50) .
Analysis of several different TCGA-datasets revealed enhanced Y5R expression in high-risk compared with low-risk (based on prognostic index) HCC patient groups.
Furthermore, high Y5R expression was also associated with poor overall and recurrence free survival (Figure 2G; Figure S2F ) as well as with advanced tumor stages ( Figure S2G ) in HCC patients. In line with this, immunohistochemical analysis of human HCC tissues derived from a further patient cohort (tissue micro array) confirmed that high Y5R expression was correlated with poor patient survival ( Figure   2H ; Figure S2H ; Table S2 ) and advanced tumor stages ( Figure 2I ; Table S2 ).
In summary, these data indicated enhanced Y5R expression in HCC as promoter of tumor progression and suggested this NPY-receptor as a prognostic and potential therapeutic target.
Y5R-inhibition impairs tumorigenicity and growth of HCC
The emerging role of the Y5R-NPY-axis in obesity (51) has inspired the development of several small molecules for pharmacologic Y5R-inhibition. "CGP71683" (Y5R-Inh) ( Figure 3A) inhibits Y5R with high affinity and selectivity towards other NPY-receptors ( Figure S3A) (52) . In vitro, this Y5R-inhibitor dose-dependently reduced proliferation and induced G0/G1-cell cycle arrest in human HCC cells (Figure 3B,C; Figure  S3B ,C). Clonogenicity assays revealed marked reduction of colony numbers and sizes after treatment with this inhibitor (Figure 3D) . These effects of pharmacologic Y5Rinhibition on proliferation and clonogenicity were confirmed using three further specific small molecule Y5R-inhibitors (53, 54) (Figure S3A; Figure S3D -F).
Also in murine HCC cells (including Hepa129 which originate from C3H mice (55)), Y5R was overexpressed as compared to murine hepatocytes (Figure S3G,H) , and pharmacologic Y5R-inhibition showed strong anti-tumorigenic effects in vitro ( Figure   S3I ). Hepa129 are widely used to establish orthotopic HCCs after injection into the liver of syngeneic C3H mice (42, 55) . In this model, Y5R was confirmed to be strongly 
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Y5-receptor in HCC
The strong effects of Y5R in HCC prompted us to further assess the role of its ligand NPY. We had hypothesized so far that serum-derived NPY (Figure S2A Table S4 ) and was associated with strong Y5-receptor expression by HCC cells ( Figure 4G ; Table S2 ). These data suggested that next to activation by serum-derived NPY, Y5R could drive liver cancer via direct cross-talk with hepatocyte-derived peritumorous NPY (Figure S4F) .
Thus, we aimed to functionally verify this potential NPY-Y5R-interaction. In the previous functional in vitro experiments, NPY-containing serum had been added to the cell culture medium, and here, applying an NPY-neutralizing antibody significantly reduced the proliferation of HCC cells ( Figure 5A ). Furthermore, we now applied recombinant NPY to HCC cells in serum free medium. Previous studies showed that NPY-receptors depend on Gi/0-proteins and RAS-signaling thereby inducing MAPK-ERK and PI3K-AKT-pathway activation (56, 57) . Here, we found that even high NPY doses (up to 1µM) did not affect AKT-activation in HCC cells (data not shown).
However, recombinant NPY induced clonogenicity ( Figure 5B ) as well as ERKactivation in HCC cells applying low nanomolar concentrations ( Figure 5C ). Moreover, NPY-induced ERK-activation was completely blocked by co-treatment with a specific Y5R-inhibitor ( Figure 5C) . Likewise, the synthetic high-affinity Y5R-specific agonist "BWX46" (Y5R-Ago) ( Figure S4G ) strongly induced ERK-activation in HCC cells ( Figure 5D ). Following an additional approach, we performed co-culture-experiments with (NPY-producing) hepatocytes and HCC cells ( Figure S4H) . Here, we observed significant inhibition of tumor cell proliferation after treatment with an Y5R-inhibitor or with an NPY-neutralizing antibody ( Figure 5E ). Furthermore, HCC cells treated with hepatocyte-derived (i.e. NPY-containing) supernatant ( Figure S4I ) showed strong Ki-67 expression and ERK-activation, which was significantly blocked by Y5R-inhibition ( Figure 5F; Figure S4J ).
Together, these data indicated peri-tumorous hepatocytes as so far unknown source of NPY and demonstrated that hepatocyte-derived NPY can drive liver cancer via cross-talk with Y5R on HCC cells.
Peri-tumorous NPY expression is induced by hepatic fibrosis and TGFβsignaling
Next, we wanted to get insight into the underlying mechanisms that induce peritumorous NPY expression in liver cancer, which usually develops in chronic liver disease (2, 58) . Immunohistological analysis of patient-derived tissues revealed that next to peri-tumorous hepatocytes, the strongest NPY-expression was detected around portal fields and fibrotic septa (Figure 6A,B; Figure S5A ,B).
The activation of hepatic stellate cells (HSC) is the key event of hepatic fibrosis, with activated HSC being the major source of extracellular matrix expression and deposition (59, 60) . Activation of HSC is characterized by expression of alpha-smooth muscle actin (α-SMA) and collagen type I expression (60) . Quantitative RT-PCR analysis revealed a significant correlation between NPY and collagen expression in peritumorous liver tissues of HCC patients ( Figure 6C) . Moreover, next to its localization around portal fields and septa, NPY expression strongly correlated with liver fibrosis/cirrhosis ( Figure 6D ; Table S4 ). We observed that NPY-positive hepatocytes were closely localized to areas of HSC-activation (indicated by e.g. α-SMA expression) in peri-tumorous liver tissues (Figure 6E ; Figure S5C -E; Table S4 ). Therefore, we excluded that NPY could also be derived directly from HSC by applying ELISA and immunofluorescence analysis, revealing that NPY is exclusively expressed by hepatocytes both in vitro and in vivo (Figure 7A,B) . Considering the striking colocalization of HSC-activation and NPY-immunopositive hepatocytes, we hypothesized that activated HSC may induce NPY expression in hepatocytes. In support of this, conditioned cell culture media from activated HSC induced NPY expression and protein secretion by hepatocytes (Figure 7C,D) .
Activated HSC are a major cellular source of hepatic transforming growth factor-beta (TGFβ), which is known as one of the most important mediators of tissue fibrosis (60) .
Therefore, we used two model systems to investigate whether TGFβ could induce NPY expression in hepatocytes: i) cultured primary human hepatocytes (PHH) and ii) a hepatoblast-derived liver organoid model representing differentiated hepatocytes in a three-dimensional, in vivo-like system (61) (Figure S6A) . In both of these models, TGFβ-treatment was confirmed to induce a dose-dependent upregulation of mesenchymal markers (62) (Figure S6B Table S4 ).
Aiming to address this TGFβ-NPY-Y5R-cross-talk functionally, we established a hybrid-organoid model consisting of HCC cells and surrounding hepatocytes ( Figure   S6F -H). In this system, TGFβ induced ("peri-tumorous") NPY expression by hepatocytes and enhanced HCC growth, which was blocked by Y5R-inhibition ( Figure   S6I ,J).
Next to hepatic stellate cell activation, chronic liver damage is also associated with chronic inflammation (59, 60) . Accordingly, we observed that -besides HSC-activation -the NPY expression of hepatocytes correlated with the number of infiltrating CD3positive immune cells (Figure S7A,B ; Table S4 ,S5). High CD3-positive immune cell infiltration also correlated with enhanced fibrosis and high α-SMA expression in peritumorous liver tissues and was also associated with reduced survival (Figure S7B ; Table S5 ). We hypothesized that although activated HSC are considered to be a major cellular source of hepatic TGFβ (60), immune cells further contribute to (NPY-inducing)
TGFβ-production in the HCC microenvironment. Moreover, further cytokines could affect NPY expression. Screening of several inflammatory cytokines that are known key drivers of chronic liver injury revealed strong correlation of IL-1β and IL-6 with NPY expression in peri-tumorous liver tissues (Figure S7C) , while other cytokines including e.g. TNF-α (data not shown) showed no correlation with NPY expression. Treatment with recombinant IL-1β caused a moderate but significant increase of NPY-expression by hepatocytes ( Figure S7D ,E). In chronic liver disease, IL-1β is secreted both by activated hepatic stellate cells (63) and immune cells (64) . In contrast to IL-1β, IL-6 treatment did not directly affect NPY expression ( Figure S7D,E) . However, IL-6 might indirectly promote NPY expression by induction of HSC-activation (65) .
In summary, we found that hepatic fibrosis and inflammation induced hepatic NPYinduction and identified TGFβ as a novel major mediator of (hepatic) NPY expression.
Our data further supported that TGFβ-induced NPY derived from (peri-tumorous) hepatocytes can drive liver cancer via cross-talk with Y5R.
Hepatocyte-derived NPY mediates chemotaxis via activation of Y5R
Besides the observed NPY effects on proliferation and clonogenicity of HCC cells, Y5R has also been described to have chemoattractive characteristics in bone marrow stem cells (66) . Therefore, we hypothesized that the NPY-gradient induced by i) downregulation of NPY in HCC cells and ii) marked NPY expression by peri-tumorous hepatocytes could impact chemotaxis of HCC cells (Figure 8A) . According to this hypothesis, high peri-tumorous NPY expression was shown to correlate with poor patient survival ( Figure 4F Figure   8G ). The molecular link between MAPK-ERK-activation and chemotaxis is well-known in cancer (67) . In line with this, we had found marked induction of ERK-signaling by NPY-Y5R-cross-talk between hepatocytes and HCC cells (Figure 5C,D,F) . Moreover, strong ERK-activation of HCC cells was exclusively detected at the boarder of tumors in the orthotopic HCC model (i.e. the site of strong NPY expression by tumorsurrounding hepatocytes) ( Figure 8H ).
Next to ERK-activation, NPY-receptors can inhibit cAMP via activation of Gi-proteins (68) . In contrast, induction of cAMP-signaling was shown to reduce HCC cell migration (69) . Therefore, we hypothesized that NPY could mediate its pro-migratory/-chemotactic effects also via Y5R-mediated cAMP-inhibition (in addition to ERKinduction). Bioluminescence resonance energy transfer (BRET) analysis revealed significant and dose-dependent inhibition of forskolin-induced cAMP-activation in HCC cells by NPY which was reduced by Y5R-inhibition ( Figure 8I) as well as inhibition of forskolin-induced cAMP-activation by Y5R-agonist-treatment ( Figure 8J) .
Functionally, the cAMP-inductor forskolin reduced migration of HCC cells which was (partly) rescued by both NPY and the Y5R-agonist BWX46 (Figure 8K) . These data suggested that both NPY-Y5R-induced ERK-activation and cAMP-reduction promote chemotactic migration of HCC cells at tumor-parenchyma boarders. Moreover, immunohistochemical analysis of human HCC tissues revealed that enhanced peritumoral NPY-expression by hepatocytes was significantly associated with stromal invasion (Fisher's exact P = 0.001). In line with this, next to migration, NPY also induced chemotactic invasion of HCC cells (Figure 8L) .
Together, these findings indicated that in addition to its effect on tumor growth, (peritumorous) NPY cross-talks with Y5R to induce chemotactic migration and might thereby drive invasion and dissemination of HCC cells.
TGFβ induces Y5R expression in HCC cells at sites of stroma-invasion
The strong effects of NPY on chemotaxis and invasion prompted us to further explore Y5R-expression at sites of stroma-invasion. At the invasive front, Y5R was even stronger expressed in HCC cells than in central tumor areas ( Figure 9A) . Moreover, immunohistochemical analysis revealed that enhanced Y5R expression significantly correlated with stromal invasion in human HCC (Fisher's exact: P = 0.041; Spearman correlation: R = 0.24; P = 0.007). In search for the underlying mechanisms, we considered TGFβ which was found to be highly expressed in the peri-tumorous regions Conversely, treatment with recombinant NPY or the specific Y5R-agonist induced SNAIL expression in HCC cells (Figure S9H) . Moreover, we found that incubation with NPY or the specific Y5R-agonist also induced chemokinetic (i.e. non-directed) migration of HCC cells via Y5R-activation ( Figure 9G; Figure S9I ) in addition to the above described chemoattractive effects. Therefore, considering the strong local coexpression of TGFβ, Y5R and NPY at sites of stroma invasion, TGFβ might promote HCC cell dissemination (75) by activation of the Y5R-NPY-axis. Accordingly, Boyden chamber assays confirmed that pre-treatment with TGFβ induced the migratory activity of HCC cells which was completely blocked by Y5R-inhibition (Figure 9H) . Considering these findings, we hypothesized that TGFβ might also (co)-regulate the age-dependent Y5R expression that we had observed in the experimental C3H mouse model and in liver tissues of HCC patients (Figure 1; Figure S1 ). However, we found that neither in in C3H mice nor in human tissues, TGFβ correlated (positively) with age or with ageassociated Y5R expression, respectively (Figure S9J-L) .
In summary, these findings indicated that TGFβ is not only a so far unknown inducer of (hepatic) NPY expression but also promotes the expression of the NPY-receptor Y5R in cancer cells at the site of stromal invasion via activation of the canonical TGFβ-TGFBR1/2-dependent pathway. Moreover, our data suggest that at least part of the TGFβ-TGFBR1/2-signaling mediated effect on EMT and stroma-invasion is mediated via Y5R-activation.
Y5R-activation is augmented by dipeptidylpeptidase 4 overexpression in HCC
In contrast to Y5R, the Y1-and Y2-receptor subtypes were not regulated by TGFβsignaling (data not shown). Furthermore, YR1 and YR2 were not overexpressed in murine and human HCC and revealed no oncogenic functions in liver cancer (Figure S10A-S). Therefore, Y5R was identified to be the only NPY-receptor that serves as a potent candidate oncogenic target in liver cancer.
The so called "NPY-converting enzyme" dipeptidylpeptidase-4 (DPP4) is a cell surface enzyme which has also a soluble form. DPP4 terminates the Y1R-activity of NPY by cleaving Tyr1 and Pro2 from NPY1-36 to form NPY3-36, which more specifically activates Y5R (76, 77) . Just recently, it has been described that hepatocytes secrete DPP4 and herewith promote insulin resistance and adipose tissue inflammation in obese patients (78) . We therefore asked whether DPP4-induced "NPY-conversion" to Y5R-specific NPY3-36 might contribute to Y5R-mediated HCC progression. We found that DPP4 expression levels were markedly increased in human HCC cell lines compared with poor expression in hepatocytes (Figure 10A) . Also applying several patient-derived datasets including TCGA-data as well as in our patient-derived samples, we detected a strong overexpression of DPP4 levels in HCC tissues as compared with (corresponding) non-tumorous liver tissue (Figure 7B-D) . In hepatocytes, DPP4 was described to be mainly localized on the bile canalicular surface (79) . We detected a similar distribution of DPP4-immonoreactivity in peri-tumorous patient tissues and strong expression in most HCC tissues. In some tumor tissues (but not in nontumorous liver tissues), the HCC cells revealed strong DPP4-expression on the entire cell membrane, which could be explained by a loss of polarity of cancer cells ( Figure   10E ; Figure S11A ). Confirming in vitro, in silico and in vivo analysis of DPP4 (mRNA) expression levels, DPP4-immunoreactivity revealed strongly enhanced protein expression in most HCC tissues as compared with non-tumorous liver tissue ( Figure   10E,F; Figure S11A ). In line with these data, potential interaction of DPP4 with the NPY-Y5R-axis in HCC was supported by strong correlation of DPP4 and Y5R expression levels in HCC patient-derived tissue samples (Figure S11A,B) as well as by co-upregulation of DPP4 and Y5R mRNA expression in HCC compared with corresponding non-tumorous tissues (Figure S11C) . High DPP4 protein expression in HCC cells also correlated with peri-tumorous NPY expression ( Table S6) . Analysis of a TCGA-derived HCC patient cohort revealed that high expression of DPP4 by itself showed a (non-significant) trend towards correlation with poor survival (Figure S11D) .
However, combined elevated tumorous DPP4 and Y5R expression together with enhanced peri-tumorous NPY expression was significantly correlated with poor HCC patient survival (Figure S11E) . Together, these data supported that NPY derived from peri-tumorous hepatocytes could be locally converted by DPP4 to enhance Y5Ractivation and receptor-subtype-specificity to drive liver cancer.
Based on these findings and hypotheses, we aimed to functionally analyze the impact of DPP4-inhibition on the pro-tumorigenic action of Y5R in HCC cells. Therefore, RNAimediated specific knockdown of DPP4 was performed in HCC cells (Figure S11F) .
Applying serum-supplemented (i.e. NPY-containing) culture media, subsequent analysis revealed strong reduction of both clonogenicity (Figure 11A ) and proliferation ( Figure 11B ) of HCC cells after DPP4-knockdown. In contrast, Boyden chamber analysis of migration applying serum-free (i.e. without NPY) culture media as a chemoattractant showed no effect of DPP4-knockout, while enhanced chemotaxis mediated by recombinant NPY was prevented by combined DPP4-knockout ( Figure   11C ).
Besides NPY, DPP4 cleaves glucagon-like peptide 1 (GLP-1) which is strongly involved in glucose metabolism. Therefore, orally administered specific DPP4inhibitors like sitagliptin (Figure S11G ) have become clinically successful standard therapeutic agents for type 2 diabetes (80) . Here, we used sitagliptin to confirm the effects of DPP4-knockout on NPY-mediated Y5R-activation as well as to analyze the use of "gliptins" as a potential pharmacologic application to target the DPP4-NPY-Y5Raxis in HCC. Sitagliptin dose-dependently reduced proliferation of HCC cells in serum (i.e. NPY)-containing culture medium (Figure S11H) , and this inhibitory effect was rescued by the specific Y5R-agonist "BWX46" (Figure 11D) . Moreover, NPY-induced chemotaxis of HCC cells was significantly reduced by sitagliptin (Figure 11E) . In contrast, sitagliptin did not affect chemotaxis-induction by the specific Y5R-agonist ("BWX46") which has no DPP4-cleavage-site ( Figure 11F) .
Together, these data indicated that Y5R-stimulation in HCC is promoted by DPP4induced NPY-conversion to truncated NPY3-36 which terminates Y1R-and augments Y5R-specificity ( Figure 11G) . Our findings suggest DPP4-inhibition using clinically established drugs as a further promising therapeutic strategy to target the newly identified NPY-Y5R-axis in HCC.
DISCUSSION
Numerous studies suggested that the NPY-system might play a critical role in aging and lifespan as well as in further cancer-related hallmarks (17, (19) (20) (21) (22) (23) (24) 51) .
Hypothalamic NPY levels decrease in aged animals (18) , and a reduced cerebral NPY production could contribute to altered reproductive function and food intake in aged subjects (81) . In contrast, activation of the NPY-system was shown in several human disorders including chronic liver disease (25, 26, 82) as well as hepatic glucose (29) and lipid (30) metabolism, but its potential role in liver cancer was unknown.
In this study, we found that the expression of the Y5-NPY-receptor (Y5R) in peritumorous liver tissues increased with age both in a mouse model and in patients. This might reflect a compensatory upregulation of Y5R due to low systemic levels of its ligand NPY in aged humans (83) . Furthermore, it might result from age-related alterations of methylation of the Y5R promotor. After malignant transformation, HCC cells take advantage from a further upregulation of Y5R expression, which is induced by microenvironment-derived factors including TGFβ. Moreover, in addition to systemic serum derived NPY, Y5R gets activated via cross-talk with local NPY derived from peritumorous hepatocytes.
Deciphering the underlying mechanisms of peri-tumorous NPY secretion by hepatocytes, we revealed that hepatic fibrosis contributes to NPY-induction and identified TGFβ-TGFBR1-signaling as a major novel mediator of NPY expression by hepatocytes. Strikingly, TGFβ is considered to be a potent modulator of fibrosis and HCC development (84) (85) (86) .
Conversely, we found that non-Y5-NPY-receptors (Y1R and Y2R) were downregulated and did not have tumor promoting functions in HCC. Actually, Y1R even revealed suppressive effects on tumor cell migration, which is in accordance with the only study that investigated the potential function of a NPY-receptor in liver cancer so far (87) . In line with our findings, Lv et al. observed that Y1R is downregulated in HCC and that forced overexpression of Y1R mediates tumor suppressor functions in HCC cells (87) .
In contrast to this single study on Y1R function, the potential roles of NPY, Y2R and Y5R in HCC had been entirely unknown. Here, we show for the first time that the NPY-Y5R-axis mediates proliferation, stemness-associated properties, chemotactic migration and invasion in liver cancer. A previous study found that stimulation of the Y1-receptor could induce TGFβ secretion by macrophages and herewith affected neuroprotection and hematopoietic stem cell survival in the bone marrow (88) .
However, to the best of our knowledge, a (converse) regulation of the NPY-system by TGFβ has not yet been described.
Here, we revealed that NPY expression in hepatocytes and Y5R expression in HCC cells, respectively, are regulated via TGFβ-TGFBR1-signaling. Furthermore, our study indicated that TGFβ-mediated effects on HCC tumorigenicity are at least in part mediated by Y5R activation. Besides canonical (TGFBR1-dependent) signaling, TGFβ can also activate Smad1/5/8 (i.e. BMP-associated) pathways through Activin Receptor-Like Kinase 1 (ALK1) together with TGFBR2 (89). Indeed, ALK1-dependent signaling represents a potential alternative mechanism of TGFβ-signaling in HCC and the ALK1-inhibitor dalantercept is currently investigated in clinical trials in HCC patients (90) . However, our study provides mechanistic evidence that the effects of TGFβsignaling on the NPY-Y5R-axis in HCC are mediated via the canonical, TGFBR1related pathway. Therefore, pharmacologic inhibition of the TGFβ-TGFBR1-axis might represent a potential strategy to target the NPY-Y5R-axis in HCC.
We further found that the NPY-converting enzyme DPP4 is upregulated in HCC and augments Y5R function. DPP4 was recently linked to aging and has been shown to be involved in age-dependent dysfunction of bone and hematopoietic regeneration (91) .
Moreover, a recent study reported that hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance (78) , further promoting the value of clinically established DPP4-inhibition for the treatment of (different components) of the metabolic syndrome and its complications. Here, we found that Y5R-stimulation in HCC is promoted by DPP4-induced NPY-conversion which terminates Y1R-and augments Y5R-specificity. Thus, our study suggests that next to direct targeting of Y5R or the TGFβ-TGFBR1-NPY-Y5R axis, DPP4-inhibition might represent a further attractive therapeutic strategy for controlling liver cancer.
Regarding potential further therapeutic applications, we revealed that the NPY-Y5Raxis activates MAPK-ERK-signaling. Therefore, future studies could examine if Y5R might contribute to efficacy and/or therapy resistance of current first-line therapeutic options for advanced HCC (e.g. sorafenib) that are known to target the RAF-ERK-axis.
In summary, targeting the TGFβ-NPY-DPP4-Y5R axis could represent a novel therapeutic avenue in HCC and also other types of cancer.
EXPERIMENTAL PROCEDURES
Animal models
Eighteen months old male C3H/HeN mice were used as a model system of age-related spontaneous hepatocarcinogenesis as described (32) (33) (34) (35) (36) (37) (38) . A murine orthotopic HCC allograft model (42) was used to analyze the therapeutic effect of the specific small molecule Y5R-inhibitor "CGP71683" (52) as well as the effect of RNAi-mediated Y5Rknockout. Animals were obtained from Charles River Laboratories (Sulzfeld, Germany) and housed under specific pathogen-free and controlled conditions.
Human cells and tissues
Pairs of human HCC tissues and corresponding non-tumorous liver tissues were obtained from patients after partial hepatectomy. Informed consent was obtained through the Human Tissue and Cell Research (HTCR) foundation (92) . The samples were immediately snap-frozen and stored at -80°C.
The tissue micro array (TMA) consisted of paired HCC and corresponding nonneoplastic liver tissues which were obtained from HCC patients undergoing surgical resection and was previously described (42) .
Statistical analysis
Results were expressed as mean ± SEM. Comparison between groups was made , HepG2 (n = 3)) compared with primary human hepatocytes (PHH, n = 5); below, representative Western blot images depicting DPP4 protein expression in HCC cells (n = 2). (B) DPP4 RNA expression levels in HCC compared with non-tumorous liver tissues (non-HCC) in different patient datasets ("Mas Liver", non-HCC: n = 19, HCC: n = 38; "Roessler Liver 2", non-HCC: n = 220, HCC: n = 225; "Wurmbach Liver", non-HCC: n = 10, HCC: n = 35; "Archer Liver", non-HCC: n = 47, HCC: n = 16) applying the Oncomine TM database (box and whisker plots (min to max)). (C) Y5R expression in TCGA-derived HCC tissues (n = 369) compared with matched non-tumorous liver tissues (non-HCC) (n = 160) applying the "Gene Expression Profiling Interactive Analysis" (GEPIA) database. The expression data were first log2(TPM+1) transformed for differential analysis. (D) DPP4 mRNA expression (quantified by quantitative RT-PCR analysis) in paired human HCC and corresponding peri-tumorous liver tissues ("non-tumor") (n = 31). (E) Representative immunohistochemical DPP4 staining (and HE-staining) (40fold magnification) in HCC and corresponding peri-tumorous liver tissues of the same patients (n = 213). Blue arrows depict the typical bile-canalicular staining pattern of DPP4 in non-tumorous hepatocytes. (F) Quantification of immunohistochemical DPP4 expression in HCC compared to corresponding peritumorous liver tissues of the same patients (n = 213). Data are presented as mean ± SEM. Statistical significance was determined by ordinary one-way ANOVA together with Dunnett′s multiple comparisons test (A,C), 2-tailed, unpaired t-test (B), 2-tailed, paired t-test (D), or by two-sided Fisher′s exact test together with Spearman correlation analysis (F). **P < 0.01, ***P < 0.001, ****P < 0.0001. 
